Anticancer prodrug for overcoming drug resistance
US11241501B2 · kind B2 · utility
0Cited by
0References
4Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 22, 2019 |
| Grant date | Feb 8, 2022 |
| Priority date | — |
| Expiry date | Aug 22, 2039 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/54
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is an anticancer prodrug that disturbs energy metabolism in cancer cells to overcome drug resistance. The anticancer prodrug has a structure including a pyruvate dehydrogenase kinase (PDK) inhibitor moiety, a mitochondrial targeting group, and an anthracycline moiety reversibly connected to the PDK inhibitor moiety and the targeting group.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.